Demyelinating disease and hepatitis B vaccination: Is there a link?

Drug Safety

Volumn 24, Issue 4, 2001, Pages 249-254

  Jefferson, T ^a   Heijbel, H ^b  

^a UK COCHRANE CENTRE   (United Kingdom)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

AUTOIMMUNITY; DEMYELINATING DISEASE; DRUG EFFECT; DRUG SAFETY; HEPATITIS B; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RECIPIENT; REVIEW; RISK ASSESSMENT; VACCINATION;

EID: 0035029693     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124040-00002     Document Type: Review

References (24)

1. Hepatite B: Les dangers du vaccin reconnus
2. Post-marketing surveillance for neurological adverse events reported after hepatitis B vaccination. Experience of the first three years
3. Central nervous system demyelination after immunisation with recombinant hepatitis B vaccine
4. School-based hepatitis B vaccination programme and adolescent multiple sclerosis
5. Premier episode de demyelinisation du système nerveux central et vaccination contre l'hèpatite B
6. Comparative safety of two recombinant hepatitis B vaccines in children: Data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD)
7. No increase in demyelinating diseases after hepatitis B vaccination
8. Major adverse reactions to yeast-derived hepatitis B vaccines: A review
9. Is there a causal link between hepatitis B vaccination and multiple sclerosis?
10. Vaccination and the risk of relapse in multiple sclerosis
11. Hepatitis B vaccination and the risk of multiple sclerosis
12. Using evidence to resolve clinical controversies: Is aggressive antihypertensive therapy harmful?
13. The quest for trials on the efficacy of human vaccines. Results of the handsearch of 'Vaccine'
14. Relation between experimental and non-experimental study designs. HB vaccines: A case study
15. Vaccine safety - Improving monitoring
16. Study of the safety, immunogenicity and seroconversion of a hepatitis-B vaccine in malnourished children of India
17. Evaluation of the immunogenicity and reactogenicity of a new combined diphthera, tetanus, whole-cell bordetella pertussis and hepatitis B vaccine and haemophilus influenzae type b (DTPw-HBV/Hib) vaccine in children at 3, 4.5 and 6 months age
18. Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children
19. Comparative study of the immunogenicity and safety of two doses of recombinant Hepatitis B vaccine in healthy adolescents
20. Comparison study of the immunogenicity and safety of 5- and 10-g dosages of a recombinant hepatitis B vaccine in healthy infants
21. Multiple sclerosis and vaccination against hepatitis B: Analysis of risk benefit profile